CD8A and neoplasm: Bone marrow cells inhibit CD8+ T cell anti-tumor activity by inducing expression of PD-L1 by tumor cells in an epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK)-dependent manner [67].